» Download Public Reports
About 3 200 reports
- Company report
- June 2013
- 14 pages
... China prescription drug sales report 2012 9 opportunity in asthma and copd the initial pipeline will target drugs that currently account for over 50% of this market expectations of up to five drugs ...
May 2013
... An average of $1,200 combined pharmacy and medical cost savings per review. With our pilot population alone, savings are estimated at more than $650,000 a year.2 Bringing synchronization to market based ...
May 2013
... Serves as the head of global regulatory affairs at astrazeneca, inc. Over 15 y ears of experience in the drug industry, including nine years at th e fda, specifically in research and develo pment ...
May 2013
... tramadol hydrochloride pain management tramadol grunethal gmbh na cadila healthcare clopidogrel bisulfate anti-coagulant bms \ sanofi aventis plavix us$ 6 billion cadila healthcare donepezil hydrochloride ...
May 2013
... Nesses to obtain a sufficient return on in- vestment. When you look at the facts, more and more money now has to be invested before a drug hits the market. According to na t u r e re v i e w s dr u g ...
May 2013
... Fda gives 'breakthrough' designa- tion to merck skin-cancer drug by peter loftus an experimental merck & co. (Mrk) skin-cancer drug was designated as a "breakthrough therapy" by the u ...
May 2013
... To production interruptions and diminished capacity Economic choices are made where older, less profitable drugs are eliminated as new generics come to market By year-end 2012, we will see $34b in new ...
May 2013
... Of emerging contaminants in water supplies antidepressants, endocrine disruptors Impacts on aquatic life Strengthening of the regulatory framework Baseline of data for drinking water supplies Assess ...
» Purchase Premium Reports
(From $ 99 - $ 4 995)
About 700 reports
- $ 4 995
- Industry report
- May 2013
- by Global Data
PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, ?PharmaPoint: Hepatitis C Virus - United States Drug Forecast ...
April 2013
$ 4 995
PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022 Summary Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory ...
May 2013
$ 5 174
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different American countries. The studies provide essential market information ...
May 2013
$ 5 174
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information ...
March 2013
$ 3 995
PharmaFocus: Vaccine Adjuvants in Infectious Disease Summary Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry's ?dirty little secret?. Today, ...
April 2013
$ 3 500
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth Summary The leading business intelligence provide ...
April 2013
$ 2 995
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry Summary "PharmaSphere: Early-Stage Technology ...
